Stock Events

Stock Events

SELLAS Life Sciences Group 

$3.76
195
-$0.1-2.59% Monday 08:45

Statistics

Day High
3.88
Day Low
3.68
52W High
-
52W Low
-
Volume
220,045
Avg. Volume
-
Mkt Cap
535.58M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 11
$7,209
Dec 10
$12,639
Sep 10
$4,500
Jun 10
$2,550
Mar 10
$2,550
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

13MarExpected
Q3 2025
Next
-0.08
-0.07
-0.07
-0.06
Expected EPS
-0.063333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-61.76MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SLS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ayala Pharmaceuticals
ADXS
Mkt Cap2.18M
Advaxis, Inc. is involved in the discovery, development, and commercialization of cancer immunotherapies, directly competing with SELLAS's cancer vaccine programs.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad oncology portfolio, including cancer vaccines and immunotherapies, competing on a larger scale with SELLAS.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. has a strong presence in the cancer immunotherapy market with products like Keytruda, competing with SELLAS's cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company offers a range of cancer immunotherapies, making it a competitor to SELLAS in the oncology market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a diversified portfolio that includes oncology products, competing with SELLAS in the development and marketing of cancer treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is involved in the discovery and development of innovative human therapeutics, including cancer treatments, competing with SELLAS's focus areas.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong oncology unit that develops cancer immunotherapies, making it a competitor to SELLAS in the global oncology market.

About

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Show more...
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Employees
15
Country
US
ISIN
US81642T2096

Listings

XNAS
US
SLS
BOATS
BOATS
SLS.BOATS
F
DE
RXK3.F

0 Comments

Share your thoughts

FAQ

What is SELLAS Life Sciences Group stock price today?▼
The current price of SLS.BOATS is $3.76 USD — it has decreased by -2.59% in the past 24 hours. Watch SELLAS Life Sciences Group stock price performance more closely on the chart.
What is SELLAS Life Sciences Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange SELLAS Life Sciences Group stocks are traded under the ticker SLS.BOATS.
What is SELLAS Life Sciences Group market cap?▼
Today SELLAS Life Sciences Group has the market capitalization of 535.58M
When is the next SELLAS Life Sciences Group earnings date?▼
SELLAS Life Sciences Group is going to release the next earnings report on March 13, 2026.
What were SELLAS Life Sciences Group earnings last quarter?▼
SLS.BOATS earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.08 USD resulting in a +21.74% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is SELLAS Life Sciences Group revenue for the last year?▼
SELLAS Life Sciences Group revenue for the last year amounts to 0 USD.
What is SELLAS Life Sciences Group net income for the last year?▼
SLS.BOATS net income for the last year is -61.76M USD.
Does SELLAS Life Sciences Group pay dividends?▼
Yes, SLS.BOATS dividends are paid quarterly. The last dividend per share was 7,209 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does SELLAS Life Sciences Group have?▼
As of February 03, 2026, the company has 15 employees.
In which sector is SELLAS Life Sciences Group located?▼
SELLAS Life Sciences Group operates in the Health Care sector.
When did SELLAS Life Sciences Group complete a stock split?▼
SELLAS Life Sciences Group has not had any recent stock splits.
Where is SELLAS Life Sciences Group headquartered?▼
SELLAS Life Sciences Group is headquartered in New York, US.